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Activation of type 1 cannabinoid receptors (CB1R) decreases GABA
and glutamate release in cortical and subcortical regions, with
complex outcomes on cortical network activity. To date there have
been few attempts to disentangle the region- and cell-specific
mechanisms underlying the effects of cannabinoids on cortical net-
work activity in vivo. Here we addressed this issue by combining in
vivo electrophysiological recordings with local and systemic phar-
macological manipulations in conditional mutant mice lacking CB1R
expression in different neuronal populations. First we report that
cannabinoids induce hypersynchronous thalamocortical oscillations
while decreasing the amplitude of faster cortical oscillations. Then
we demonstrate that CB1R at striatonigral synapses (basal ganglia
direct pathway) mediate the thalamocortical hypersynchrony,
whereas activation of CB1R expressed in cortical glutamatergic
neurons decreases cortical synchrony. Finally we show that activa-
tion of CB1 expressed in cortical glutamatergic neurons limits the
cannabinoid-induced thalamocortical hypersynchrony. By reporting
that CB1R activations in cortical and subcortical regions have
contrasting effects on cortical synchrony, our study bridges the
gap between cellular and in vivo network effects of cannabinoids.
Incidentally, the thalamocortical hypersynchrony we report sug-
gests a potential mechanism to explain the sensory “high” experi-
enced during recreational consumption of marijuana.
cannabis | high-voltage spindles | striatum | substantia nigra |
electrocorticograms
Cannabinoids are a family of compounds that activate canna-binoid receptors, which are well known for their psychotropic
effects and therapeutic potentials. The type 1 cannabinoid re-
ceptor (CB1R) is massively expressed in the brain at the synaptic
terminals of excitatory and inhibitory neurons, and its activation by
exogenous or endogenous cannabinoids decreases neurotrans-
mitter release (1–3). One largely unanswered question is how the
elementary decreases in excitatory and inhibitory synaptic trans-
missions induced by systemic intake of cannabinoids interact to
produce alterations in neuronal network activity in vivo. A number
of recent studies combining systemic injections of CB1R agonists
and antagonists with electrophysiological recordings in the hip-
pocampus and neocortex of awake or anesthetized rodents have
shown that a hallmark of cannabinoids effects on neuronal net-
work activity is a decrease in synchrony (4–9). Specifically, systemic
CB1R activation has been shown to decrease (i) the amplitude of
the hippocampal θ rhythm (4, 7, 8), (ii) the amplitude of γ oscil-
lations in the hippocampus (4, 7, 10), enthorinal cortex (8), and
prefrontal cortex (7), (iii) the incidence of hippocampal ripples (4,
6, 11), and (iv) spiking correlation in the hippocampus and pre-
frontal cortex (4, 5, 7, 9).
In contrast to the consistent reports that cannabinoids dampen
cortical network oscillations, other findings suggest that they could
also increase synchrony. First, CB1R are predominantly expressed
by GABAergic forebrain neurons (12), and their activation leads
to decreasedGABA release (1). Therefore, cannabinoids might be
expected to increase network synchrony or generate excessive
firing activity, in a similar manner to GABA receptors antagonists,
which favor convulsive seizures (13, 14). Second, several studies
have reported that cannabinoids are proconvulsant in experi-
mental models of epilepsy (15–17). The concurrent but un-
balanced activation of the CB1R at the synaptic terminals of
inhibitory and excitatory neurons could be one explanation for
these seemingly contradictory observations. Additionally, the high
level of CB1R expression in subcortical regions (18–20) leaves
open the possibility that at least a part of the cannabinoid-induced
alterations in cortical network activity has extracortical origins. To
date, the potential cell type- and region-specific impact of CB1R
activation on in vivo cortical network activity has received little
attention. Here we specifically addressed this issue by comparing
the impact of systemic and local injections of the CB1R agonist
CP55940 on cortical network oscillations recorded from freely
moving mice lacking CB1R expression in distinct neuronal pop-
ulations. The results reveal the cell- and region-specific mecha-
nisms underlying a dual modulation of cortical synchrony by
exogenous cannabinoids and pave the way to a refined under-
standing of the cognitive alterations associated with marijuana
consumption (21, 22).
Results
Systemic CB1R Activation Induces Thalamocortical High-Voltage
Spindles While Decreasing Fast Electrocorticogram Oscillations. To in-
vestigate in vivo the cell type-specific impact of systemic CB1R
activation on cortical network activity, we recorded neocortical
electrocorticograms (ECoG) before and after i.p. injections of the
high-affinity CB1R agonist CP55940 (0.3 mg/kg of body weight).
ECoG were recorded bilaterally above the somatosensory cortex,
in the home cage of two groups of mice: C57BL/6N mice (n = 9)
and conditional mutant mice that lack CB1R expression in specific
neuronal populations [n = 33, including WT littermates (19, 23,
24)]. All ECoG shown and compared in this study were taken from
periods of immobility, to avoid biased quantification of network
activity due to decreased locomotor activity induced by the sys-
temic injection of cannabinoids (19) (Fig. S1). We first examined
and quantified the impact of CP55940 on the oscillatory content of
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theECoG fromC57BL/6Nmice (Fig. 1). After CP55940 injections
the ECoG displayed numerous oscillatory bursts, with a shape,
frequency (∼5 Hz), length (∼1–2 s), and amplitude (> 0.5 mV)
characteristic of thalamocortical high-voltage spindles (HVS, also
referred to as spike-and-wave discharges/seizures) (Fig. 1 A–C;
arrowheads in Fig. 1C) (25–27). As expected for this type of os-
cillation, HVS were sparse during control recordings (27) and,
after CP55940 injections, were strictly restricted to periods of im-
mobility (28). A quantitative routine developed to compare HVS
before and after CP55940 injections (Experimental Procedures, Fig.
Fig. 1. Systemic CB1R activation induces HVS while decreasing the amplitude of faster neocortical oscillations. (A–C) Single experiment showing the effects
of an i.p. injection of the CB1R agonist CP55940 (Right), or its vehicle alone (Left), on a mouse ECoG recorded during immobility epochs. (A) Thirty minutes
ECoG (black traces) and HVS incidence (colored rasters). (Scale bars, 1 mV and 5 min.) (B) Thirty seconds ECoG taken from rectangles in A. (Middle) Time–
frequency power spectrograms (1-s sliding windows, steps of 0.2 s). (Bottom) ECoG power values in the HVS frequency band (4–6 Hz). Dashed line is HVS
detection threshold. Circles identify windows detected as part of an HVS. (C) Similar to B, but 10 s ECoG are from dashed rectangles in B. Arrowheads indicate
detected HVS. ECoG traces in A–C have the same voltage scale. (D and E) HVS comparison in all experiments. Each line represents a single experiment, and
different colors represent different animals. CP55940 (CP, 0.3 mg/kg) reliably increases HVS, and this effect was reversed (D) and abolished (E) by injection of
the CB1R antagonist AM251 (AM, 3 mg/kg). (F and G) Similar to D and E, but the amplitude of ECoG oscillations faster than 12 Hz is compared. Same
experiments and color code as in D and E. P values in D–G are from Wilcoxon paired two-sided signed rank test. Bold green traces in D and F show the
quantification of the illustrative experiment shown in A–C.
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1 B and C, and Fig. S2) showed that, across animals and experi-
ments, HVS incidence and power reliably and strongly increased
after CP55940 injections (Fig. 1D). This effect was dependent on
CB1R activation because it was completely reversed (Fig. 1D and
Fig. S3) and prevented (Fig. 1E) by i.p. injections of the CB1R
antagonist AM251 (3 mg/kg). Cannabinoids have been previously
shown to decrease the power of neocortical local field potential
oscillations over a wide range of frequencies (7, 8). Therefore, we
next quantified the effect of CP55940 on ECoG oscillations in a
frequency band distinct from the one of the cannabinoid-induced
HVS. As expected, CP55940 injections reliably decreased the
amplitude of fast (>12 Hz) ECoG oscillations (Fig. 1F) (7, 8), an
effect that was also reversed (Fig. 1F and Fig. S3) and blocked (Fig.
1G) by AM251 injections. Taken together these data show that
systemic CB1R activation, although decreasing synchrony of fast
ECoG oscillations, generated hypersynchronous oscillatory bursts
characteristic of thalamocortical HVS.
CB1R Activation at GABAergic Striatonigral Synapses Increases the
Incidence of Thalamocortical HVS. We next set out to understand
how CP55940 i.p. injections increase HVS. Although rodent HVS
function is still a matter of debate [analog to human μ rhythm (29)
or model for absence-like seizure actvity (30)], there is ample ev-
idence that they share mechanistic similarities with the well-stud-
ied thalamocortical sleep spindle oscillations (31–35). On the one
hand, the basal ganglia is a major site controlling thalamocortical
oscillations (28, 36) via giant inhibitory nigrothalamic synapses
(37). Specifically, potentiation or blockade of GABAergic trans-
mission in the substantia nigra pars reticulata (SNr) decreases or
increases HVS incidence, respectively (36, 38). On the other hand,
the highest density of CB1R in the brain is found in the SNr on
striatal inhibitory terminals (1, 20), where CB1R activation potently
decreases GABA release (39). To test the hypothesis that CB1R
expressed by striatonigral neurons (D1-positive medium spiny neu-
rons forming the basal ganglia direct pathway) mediate the increase
in HVS observed after systemic injection of CP55940, we took ad-
vantage of conditional mutant mice lacking CB1R expression in the
striatal neurons projecting to the SNr (D1-CB1R−/− mice) (19). In
WT mice, CP55940 systemic injections induced HVS (Fig. 2A), but
no such effect was seen in the D1-CB1R−/− mice (Fig. 2 B and C).
CP55940 effects on HVS were also abolished in GABA-CB1R−/−
and CaMK-CB1R−/−mice (Fig. S4), which lack CB1R expression in,
respectively, GABAergic and principal forebrain neurons (24). In
GABA-CB1R−/− and CaMK-CB1R−/− mice, striatal neurons pro-
jecting to the SNr lack CB1R expression. Thus, this result (Fig. S4)
confirms that CB1R expressed by striatonigral neurons is required
for the CP55940-induced increase in HVS. Importantly, the ECoG
oscillatory content during baseline recordings was similar across all
types of conditional mutant mice (Fig. S5), ruling out the possibility
that the differential effects of CP55940 in WT and CB1R mutant
mice originate from alterations in baseline cortical network activity.
The lack of cannabinoid-induced enhancement in HVS in
D1-CB1R−/− mice suggested that, in the SNr, activation of CB1R
expressed by striatonigral neurons is necessary to increase HVS.
To test more directly this hypothesis, CP55940 was locally injected
in the SNr of WT and D1-CB1R−/− mice. In WT mice, injections
of CP55940 in the SNr induced HVS, an effect that could be re-
versed by a subsequent injection of the GABA-A receptor agonist
muscimol (Fig. 3 A and B). Conversely, in D1-CB1R−/− mice,
intra-SNr injections of CP55940 failed to increase HVS (Fig. 3 C
and D; P < 0.001 vs. WT data), whereas subsequent injections of
the GABA-A antagonist bicuculline increased HVS (Fig. 3C).
Altogether these results are consistent with a scenario in which
CP55940 enhances HVS incidence by decreasing GABA release
from direct pathway striatal neurons projecting to the SNr.
Activation of CB1R Expressed by Cortical Glutamatergic Neurons
Decreases Fast Neocortical Oscillations and Limits Cannabinoid-Induced
Increase in HVS.Systemic injection of CP55940 enhances HVSwhile
decreasing the power of fast (>12 Hz) ECoG oscillations in mice
Fig. 2. CB1R expressed by D1-positive striatal neurons are required for the
CP55940-induced increase in HVS. (A and B) Group effect of vehicle and
CP55940 (CP, 0.3 mg/kg) injections on HVS in WT animals (A) and mice
lacking CB1R expression in D1-positive striatal neurons (D1-CB1R−/−; B). (C)
Comparison of the effects of CP55940 on HVS between WT and D1-CB1R−/−
mice. Histograms show mean changes in HVS power and incidence. Error
bars are SEM. P value is from the Wilcoxon rank sum test.
Fig. 3. Intra-SNr activation of CB1R expressed by D1-positive striatal neurons induces HVS. (A and C) Single experiments inWT (A) and D1-CB1R−/− (C) mice. (Left)
Track of the injection cannula. Black traces are ECoG during baseline and after injections (500 nL) of vehicle, CP55940 (20 mg/mL), and muscimol (0.5 mg/mL; A) or
bicuculline (0.2 mg/mL; C). Rasters show detected HVS. Colored histograms show HVS power and incidence quantification for these two experiments. (B and D)
Group effect of intra-SNr CP55940 (CP) injections on HVS in WT (B) and D1-CB1R−/− (D) mice. (Scale bars, 5 min and 1 mV.)
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(Fig. 1). To test whether these effects shared the same mechanism,
we quantified the effect of CP55940 on the amplitude of fast ECoG
oscillations in CB1R conditional mutant mice and their WT
littermates. The CP55940-induced decrease in fast ECoG oscil-
lations power was intact in D1-CB1R−/− mice (Fig. 4), suggesting
that the cannabinoid-induced increase inHVS and decrease in fast
ECoG oscillations have distinct mechanisms. In contrast, the
decrease in fast ECoG oscillations was significantly reduced in
Glu-CB1R−/− and CaMK-CB1R−/− mice compared with WT lit-
termates (Fig. 4). These results show that activation of CB1R
expressed by glutamatergic cortical neurons is, at least in part,
responsible for the reduced neuronal network synchrony observed
in vivo after cannabinoids injections. Additionally, CP55940-in-
duced decrease in fast ECoG oscillations was stronger in GABA-
CB1R−/− mice than in WT littermates (Fig. 4), suggesting that
activations of CB1R expressed on cortical GABAergic and glu-
tamatergic neurons exert a bidirectional control over fast ECoG
oscillations.
A desynchronization function of CB1R expressed by gluta-
matergic cortical neurons is additionally supported by the obser-
vation that the cannabinoid-induced increase in HVS was stronger
in Glu-CB1R−/− mice than in WT animals (Fig. 5 A–C). Indeed,
CP55940 induced prominent HVS and high-amplitude isolated
spike-and-wave complexes in the mutant mice (Fig. 5 D and E).
This result suggests that, in WT animals, activation of CB1R ex-
pressed by glutamatergic cortical neurons limits the increase in
HVS observed after CP55940 injection.
Discussion
Here we report that cannabinoids have contrasting effects on
neocortical network synchrony, characterized by the appearance of
hypersynchronous thalamocortical oscillations and decreased
amplitude of fast ECoG oscillations. Taking advantage of con-
ditional mice lacking CB1R expression in specific neuronal pop-
ulations, we broke down these effects into region- and cell-specific
CB1R activation: CB1R at striatonigral inhibitory synapses are
responsible for the cannabinoid-induced thalamocortical hyper-
synchrony, whereas CB1R activation at cortical excitatory syn-
apses reduces synchrony of fast neocortical oscillations.
Fig. 4. Cannabinoid-induced decrease in fast ECoG oscillations power is
reduced in mice lacking CB1R in glutamatergic cortical neurons. (A) Effects
of vehicle and CP55940 (CP) injections on the amplitude of fast (>12 Hz)
ECoG oscillations in, from left to right, WT, D1-CB1R−/− mice, mice lacking
CB1R in glutamatergic cortical neurons (Glu-CB1R−/−), in all principal fore-
brain neurons (CaMK-CB1R−/−), and in all GABAergic forebrain neurons
(GABA-CB1R−/−). (B) Mean changes in HVS and SEM for WT and mutant mice.
P values are fromWilcoxon rank sum test vs. WT data. Dotted lines represent
mean change in the WT group.
Fig. 5. CB1R expressed by glutamatergic cortical neurons limit the cannabinoid-induced increase in HVS. (A and B) Effects of vehicle and CP55940 (CP)
injections on HVS incidence and power in WT (A) and Glu-CB1R−/− (B) mice. (C) Comparison of the mean changes in HVS for these mice. (D) Single experiment
in which ECoG (black) was recorded from a Glu-CB1R−/− mouse after vehicle (Upper) and CP55940 (Lower) i.p. injections. Colored rasters show detected HVS.
(Scale bar, 5 min.) (E) Upper trace is taken from the rectangle in D. Arrowheads show two HVS. The two lower traces are taken from the upper trace (1, 2) and
show, respectively, a strong HVS and isolated spike-and-wave seizure-like discharges. (Scale bars, 1 s and 0.75 mV.)
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We found that in immobile mice, systemic CB1R activation
generated highly synchronous oscillatory bursts of the ECoG with
a frequency, duration, and amplitude characteristic of thalamo-
cortical HVS (25, 26, 40). We further showed that this hyper-
synchronous effect was mediated by CB1R located in the SNr on
striatal GABAergic synaptic terminals. Finally, intra-SNr injec-
tions of GABA-A agonist and antagonist, respectively, reversed
and mimicked the effects of CP55940 on HVS. Altogether, our
results are best explained by the following mechanism: systemic
CB1R activation induces thalamocortical HVS by decreasing
GABA release at striatonigral synapses (Fig. 6). This hypothesis is
supported by previous studies on CB1R synaptic physiology in the
basal ganglia and the known role of the SNr in controlling thala-
mocortical oscillations. First, the highest level of CB1R immuno-
reactivity in rodent is found in the SNr (18). In this nucleus, CB1R
is localized on axons and terminals of striatal neurons (20), and its
activation potently inhibits striatonigral GABAergic transmission
(20, 39). Second, the basal ganglia are known to modulate thala-
mocortical oscillations (28, 36). Specifically, hyperpolarization of
thalamocortical relay cells is a condition sine qua non for the
emergence of thalamocortical oscillations (13, 31, 34), and the
giant inhibitory synapses between GABAergic neurons of the SNr
and thalamocortical relay cells have been proposed to contribute
to this hyperpolarization (37). In agreement with an oscillation-
promoting role of nigrothalamic cells, pharmacological excitation
or inhibition of SNr neurons increased or decreased HVS in-
cidence, respectively (38, 41). Finally, dopamine depletion or
blockade of dopamine receptors in the striatum, which decreased
the activity of direct pathway striatal neurons (42), also enhanced
the incidence of HVS (28, 43). Altogether these studies suggest
that the cannabinoid-induced increase in HVS we report is best
explained by the disinhibition of nigrothalamic GABAergic neu-
rons (Fig. 6).
In mice lacking CB1R on glutamatergic cortical neurons (Glu-
CB1R−/−), the cannabinoid-induced increase in HVS was stronger
than in their WT littermates, and CP55940 generated a seizure-
like pattern of activity. This result suggests that in WT mice, stria-
tonigral and cortical CB1R compete and modulate thalamocortical
oscillations in opposite directions. The partial counterbalancing
effect of “cortical” CB1R could be due to a decrease in release of
glutamate in the neocortex, in the thalamus (from corticothalamic
excitatory neurons), or in both areas. This is in agreement with
a role of cortical input on the thalamic reticular neurons to control
thalamocortical HVS oscillations (34, 44). A role for CB1R
expressed by cortical glutamatergic neurons in reducing network
synchrony is further supported by the observation that cannabi-
noid-induced decrease in fast neocortical oscillations was reduced
in Glu- and CaMK-CB1R−/− mice. This function is in line with
studies showing that “glutamatergic cortical” CB1R provide pro-
tection against kainic acid-induced seizures (23, 24) and with re-
cent works suggesting that cannabinoids decrease hippocampal γ
and ripple oscillations by decreasing excitatory transmission (6,
11). CB1R expressed by brain astroglial cells have been recently
shown to participate in the control of glutamatergic synaptic
transmission and plasticity (45–47). Our results suggest that the
effects of CP55940 on fast ECoG oscillations are mostly in-
dependent from astroglial CB1R: in fact, at odds with astroglial
CB1R-dependent long-term depression of excitatory synaptic
transmission (47), CP55940 effects were reversed by injections of
a CB1R antagonist and were significantly reduced inGlu-CB1R−/−
mice. Still, at this stage, we cannot entirely exclude that astroglial
CB1R contribute to the decrease in fast ECoG oscillations, and
future investigation will address directly this possibility.
There are several possible specific behavioral implications of
our findings. First, the reported dual pro- and antioscillatory
functions of CB1R expressed in, respectively, subcortical and
cortical regionsmight be related to the complex control of network
excitability exerted by CB1R in physiopathological conditions,
such as during epileptiform seizures (15–17, 23, 48). Additionally,
we believe that the increase in thalamocortical HVS after CB1R
activation in the SNr offers a perspective to understand the psy-
choactive effects associated with marijuana consumption. In this
context, it is important to emphasize that thalamocortical HVS
have been proposed to constitute a brain state that facilitates de-
tection of weak sensory stimulation (29, 49). More generally, the
activity of the thalamocortical system controls vigilance states and
gates the perception of sensory stimulation (50). The recreational
consumption of marijuana is well known to produce a “high”
characterized by an altered consciousness and an intensification of
sensory perceptions (51). Strikingly, in both human and rodent
brains, the highest expression of CB1R is found in the SNr on
striatonigral synapses (18, 20, 52, 53). Therefore, an exciting hy-
pothesis for future investigation is that the sensory/behavioral
“high” experienced during marijuana consumption is due to an
aberrant thalamocortical synchrony via massive CB1R activation
in the SNr.
Experimental Procedures
Experimental procedures are described in SI Experimental Procedures. This
section describes the conditional CB1R mutant mice used, electrophysiological
recording methods, local and systemic pharmacological injections, and
data analysis. All animal procedures were conducted in accordance with
standard ethical guidelines (European Communities Directive 86/60-EEC) and
were approved by the local ethical committee (Comité d’Experimentació
Animal, Universitat de Barcelona, Ref 520/08).
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Fig. 6. Hypothesized mechanism responsible for the cannabinoid-induced
thalamocortical HVS. (A and B) Schematic representation of the circuit re-
sponsible for HVS control during vehicle (A) or CB1R agonist (B) injections.
During vehicle injection the oscillation-promoting nigrothalamic GABAergic
neurons are kept inhibited by striatonigral inhibitory neurons. After can-
nabinoid injection, the nigrothalamic oscillation-promoting neurons are
disinhibited after CB1R activation at striatonigral synapses.
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SI Experimental Procedures
All animal procedureswere conducted in accordancewith standard
ethical guidelines (European Communities Directive 86/60-EEC)
and were approved by the local ethics committee (Comité d’Ex-
perimentació Animal, Universitat de Barcelona, Ref 520/08).
Animals. In vivo chronic electrocorticogram (ECoG) recordings
were performed in three groups of animals: (i) 9C57BL/6N (Charles
River), (ii) conditional type 1 cannabinoid receptor (CB1R) mutant
mice (4Glu-CB1R−/−, 5 GABA-CB1R−/−, 4 CaMK-CB1R−/−, and
7 D1-CB1R−/−), and (iii) 13 WT littermates (1–3). All mice (male
and female) were aged 4–7 mo. Regarding ECoG baseline activity
and CP55940 effects on ECoG, no differences between sexes were
observed. Similarly, no differences were observed between WT
littermates of the four different mutant lines. Therefore, all WT
animals were pooled into a single group for statistical comparison.
Glu-CB1R−/−mice lack CB1R expression in dorsal telencephalon
glutamatergic neurons, including neurons located in neocortex,
paleocortex, archicortex, hippocampal formation, and cortical
portions of the amygdala; GABA-CB1R−/− mice lack CB1R ex-
pression mainly from forebrain GABAergic neurons; CaMK-
CB1R−/− mice lack CB1R expression in all forebrain principal
neurons; and D1-CB1R−/− mice lack CB1R expression in cells
expressingD1-type dopamine receptors, including striatal medium
spiny neurons (1, 2, 4). Conditional CB1R mutant mice were
generated in a predominant C57BL/6N background (back-crossed
for at least five generations) and were genotyped before and after
the experiments, as previously described (2). A few days before
surgical implantations of chronic recording electrodes, animals
were housed individually in the experimental laboratory in stable
conditions of temperature (22 °C) and humidity (60%), with a
constant cycle of 12 h light and 12 h dark and ad libitum access to
food and water. Animals were given at least 1 wk of recovery time
after the surgery before recordings started.
Surgical Procedures. All surgical procedures were performed with
stereotaxic control under deep isoflurane anesthesia. In the ma-
jority of chronic recordings performed in mice, miniature stainless
steel screws (Small Parts, size 000-120) were implanted epidurally
above the somatosensory cortex [anteroposterior (AP): −0.5 mm;
mediolateral (ML): ±3 mm, relative to Bregma). In a few mice,
recordings were additionally performed above the prefrontal
cortex (AP: +1.5; ML: ±0.75) and/or in the CA1 hippocampus
pyramidal layer. Two miniatures screws implanted above cere-
bellum served as ground and reference.
For local injectionexperiments,micewereadditionally implanted
with a single stainless steel guide cannula (26 gauge; PlasticsOne)
aimed at the dorsal border of the substantia nigra pars reticulata
(AP: −3.4 mm; ML: ±1.37 mm; dorsoventral: −2.75 mm). The tip
injector protruded 1 mm below the tip of the guide cannula.
Drugs Preparations.For i.p. injections,CP55940andAM251 (Vitro)
were dissolved in a 1:1:18 vehicle solution of DMSO (Sigma):
cremophor-EL (Sigma):saline. The volume of the injections was 10
mL/kg of body weight. The dosage for CP55940 and AM251 i.p.
injections was 0.3 and 3 mg/kg of body weight, respectively. For
local injection experiments, 10 μg of CP55940, dissolved in 0.5 μL
of vehicle (same as above), were injected. A muscimol (Tocris)
solution (0.5 μL of 0.5 mg/mL in saline) and 0.5 μL of a (-)-bicu-
culline methiodide (Tocris) solution (0.2 mg/mL in saline) were
also injected in WT and D1-CB1R−/− mice, respectively.
Chronic in Vivo Recordings and Local Injection Procedures. Wide-
band (0.1 Hz–8 kHz) neurophysiological signals (amplified 1,000
times via a Plexon HST/16V-G20 headstage and a Plexon PBX2
amplifier) and acceleration signals (1–50 Hz) were digitized at 1
kHz on two synchronized National Instruments A/D cards (PCI
6254, 16-bit resolution).
Locomotor activity was quantified either with two silver bipolar
electromyography (EMG) electrodes inserted in the dorsal nuchal
(neck) muscles or with a triple-axis miniature accelerometer af-
fixed to the recording headstage (ADXL 335, SparkFun Elec-
tronics) (5). In this last case, the signal of the accelerometer z axis
(vertical) was used.
Control recordings started 15min after connection of the animal
to the amplifier or vehicle i.p. injections. “Drug” recordings started
15 min after i.p. injections. Three types of experiments were per-
formed: (i) vehicle-CP55940, (ii) vehicle-CP55940-AM251, and
(iii) vehicle-AM251-[CP55940+AM251]. In the case of type-2
experiments, at least 2 h 30 min-long recordings were performed
after AM251 injection to allow for complete reversion of the
CP55940 effect. The ECoGs analyzed were then taken starting 1 h
30min after AM251 i.p. injection. The rationale for this is the well-
known slow reversibility of CB1R agonist effects by CB1R antag-
onist, which is explained by the lipophilic nature of CP55940 and
AM251 and the better CB1R affinity of the former vs. the latter
compound. One to three experiments were performed in each
animal, depending on the quality of the electrophysiological signal.
Experiments performed in the same animal were interleaved with
at least 5 d without any injection.
For local injection procedures in awake mice, animals were
manually restrained from the recording headstage, the dummy
cannula was gently removed, and the injector was slowly inserted
through the guide cannula. The injector was connected via a
polyethylene tube (PE50; Plastics One) to a Hamilton micro-
syringe driven by a microinfusion pump (11 plus; Harvard Ap-
paratus). A volume of 500 nLwas injected at a rate of 200 nL/min.
To allow complete diffusion of the drug, the injector was left in
place 2min after injection before being removed and replaced by
the dummy. After baseline recording, the injection order was
vehicle-CP55940-muscimol (or bicuculline in CB1R-D1−/−
mice). Electrophysiological recordings consisted of at least 20
min of immobility epochs in each condition, starting just after
local injections.
At theendof theexperiments,miceweredeeplyanesthetizedand
their brain fixed with an intracardiac perfusion of 10% formalin
solution. The brains were sliced (50 μm), and Nissl staining was
performed to confirm the position of injection cannulae.
Behavioral Activity Quantification. Neck EMG or head acceleration
signals were respectively high-pass filtered above 40 Hz and band-
passfiltered between 2 and 20Hz.Thefiltered signals were squared
and smoothedwith anaveragedfilter of 500ms.The resulting signal
provideda time-varyingestimateof behavioral activity.Because the
quality of EMG recording and the exact position of the acceler-
ometer varyacrossdaysandbetweenanimals, the thresholdvalue to
separate immobility from mobility was adjusted manually. To this
end, the time-varying behavioral estimate was overlaid with the
simultaneously recordedECoG.ECoGoscillatorycontentdepends
onbehavioral activity, and this propertywasused to adjust precisely
the threshold. The same threshold was used for control and drug
recordings to be compared. If the interval between two consecutive
mobility periods was less than 4 s, these periods were merged.
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Power Spectrum Analysis. Spectral analyzes were made using a
multitaper approach as implemented in the Chronux toolbox
(http://chronux.org/). ECoG was digitally high-pass filtered at
1 Hz. Frequency-domain analysis was restricted to data recorded
during immobility periods. Power spectrum density functions were
computed with nine tapers and averaged over 10-s–long epochs.
High-Voltage Spindles Comparison. Comparison of high-voltage
spindles (HVS) incidence and power between control and drug
conditions was made from ECoG (25–30 min long) recorded
during periods of immobility (i.e., periods of immobility, in-
terleaved by behavioral activity, were concatenated until they
amounted to 25–30 min). The rationale for comparing HVS over
such relatively short periods was to avoid as much as possible the
inclusion of slow-wave sleep in our control recordings. During
immobility, the incidence of HVS in mice was extremely low in
control condition but strongly and reliably increased after
CP55940 systemic injection (6). Noticeably, across experiments
and animals, we found variability in the mean frequency of the
HVS appearing after CP55940 injections (range, 4–8Hz). The first
step of our HVS quantification consisted therefore in determining
the cannabinoid-induced HVS frequency band. To avoid ECoG
power at low frequencies (<3 Hz) contaminating the estimation of
the HVS frequency band (owing to the presence 1/f pink noise in
this type of signal), the ECoG obtained after CP55940 injection
was detrended (locdetrend function in Chronux toolbox, 300-ms–
long moving windows). The average power spectrum density
function of the detrended ECoG was computed as described
earlier. The HVS frequency band was defined as a 2-Hz–wide
window centered around the peak of the power spectrum in the
drug condition (Fig. S2A, 1). Using a distinct method (7) to reduce
1/f pink noise in the ECoG resulted in similar results. Note that
ECoG detrending was only done to define the HVS frequency
band. CP55940 globally reduced the amplitude of the ECoG
fluctuations (Fig. 1). To avoid this effect affecting HVS detection,
the ECoGs to compare were standardized. Time–frequency
spectrograms of the standardized ECoGs were computed (1-s–
long windows, advanced in steps of 0.2 s; examples in Fig. 1C and
Fig. S2B). For each window, the power in theHVS frequency band
was calculated (Fig. S2 A, 2). An arbitrary threshold for HVS
detection was then defined as the mean plus 2 SDs of the HVS
frequency band power values obtained in all of the windows (ve-
hicle + CP55940, Fig. S2 A, 3). HVS were defined as the times
when four or more consecutive windows had power values in the
HVS frequency band superior to the threshold (Fig. 1 B andC and
Fig. S2 A, 4 and B). Finally, the time–frequency spectrograms of
the ECoGs (nonstandardized) were computed as above. In the
pharmacological conditions to compare (e.g., vehicle vs. CP55940),
we computed the sum of the ECoG power in the HVS frequency
band from the windows detected as part of an HVS (Fig. S2 A, 5).
These sums provide a quantification of HVS incidence and power
during a single experiment. It is very important to note that the
threshold is a relative value that depends on the intraexperiment
variability of the ECoG power in the HVS frequency band. For
instance, a strong increase in HVS after CP55940 injection would
bias the threshold toward a high value. Consequently, the number
of detectedHVS after vehicle injectionwould be low. Conversely, if
a CP55940 injection had little effect onHVS (as in theD1-CB1R−/−
mice), the threshold would be low and more HVS would be de-
tected in the control recording (this is the reason why baselineHVS
incidence is higher in Fig. 3C than in Fig. 3A). Using this “relative”
method to compare HVS in a given pharmacological condition
(e.g., vehicle) between different animals or experiments is there-
fore meaningless. Only change in HVS power and incidence (cal-
culated as the ratio “HVS in CP55940”/“HVS in vehicle”) were
compared across animals.
Statistics. To statistically assess electrophysiological differences
between pharmacological conditions (e.g., vehicle vs. CP55940) in
a given group of animals (e.g., WT mice) we used the Wilcoxon
paired signed rank test (nonparametric test). To statistically assess
differences in CP55940 effect between two groups of animals (e.g.,
WT vs. Glu-CB1R−/−mice) we used theWilcoxon rank sum test
(nonparametric test).
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Fig. S1. Separation of immobility from mobility periods. (A and B) Illustrative experiment during which ECoG (black) and vertical head acceleration (gray)
were recorded simultaneously. Orange and green lines show detected periods of activity and immobility, respectively. (A) Full recording; (B) 10-s epoch taken
from A, at the time indicated by the dash lines. (C) Power spectrum density function of the ECoG during immobility and activity (same color code as in A and B).
Note that the strong increase in ECoG power above 30 Hz during behavioral activity is partially accounted by contamination (via passive volume conduction) of
the ECoG with electromyographic signals (mainly showing artifacts).
Fig. S2. Method to compare the incidence and power of HVS after vehicle and CP55940 injections. (A, 1) Same-length ECoGs, recorded during immobility
epochs, are compared after systemic injections of vehicle and CP55940. Power spectra of the detrended ECoGs are computed, and HVS frequency band is
determined. (A, 2) Time-frequency spectrograms are computed from the standardized ECoG, and the time-varying power in the HVS frequency band is re-
ported. (A, 3) Threshold detection is set as the mean plus 2 SDs of all the HVS band power values (vehicle + CP55940). (A, 4) HVS are defined as at least four
consecutive windows with power values above threshold. (A, 5) The sum of the ECoG power (in the HVS band) from the windows detected as part of an HVS is
computed for each pharmacological condition and compared. (B) Examples of detected HVS. (Top) Traces are ECoG epochs taken from A, at times indicated by
stars. (Middle) Time–frequency spectrograms. White dotted lines show HVS frequency band for this experiment. (Bottom) ECoG power in the HVS frequency
band. Dashed lines represent the threshold and circled points the values detected as part of a HVS.
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Fig. S3. CP55940 effects on HVS and fast ECoG oscillations are still present 2 h 45 min after injection and are reversed by injection of a CB1 antagonist. (A) HVS
were compared in 30-min-long epochs (during immobility) starting 15 min after vehicle and both 15 min and 2 h 30 min after CP55940 injections (0.3 mg/kg, n =
6 experiments in six mice). (B) Same experiments as in A, but the amplitudes of fast ECoG oscillations (>12 Hz) were compared. P values in A and B are from
Wilcoxon paired two-sided signed rank test. (C) Average ratio between late and immediate effects of CP55940 on HVS. Comparison is made between ex-
periments in which only CP55940 was injected (left bar, same data as in A) and experiments in which an i.p. injection of AM251 was made 1 h after CP55940
injection (right bar, same data as in Fig. 1D). In both conditions late effects were quantified starting 2 h 30 min after the CP55940 injection. P value is from the
Wilcoxon ranksum test. (D) Similar comparison as in C, but for the amplitude of fast (>12 Hz) ECoG oscillations. Left bar is calculated from from data in B,
whereas right bar is from the same data as in Fig. 1F.
Fig. S4. Effect of CP55940 on HVS is abolished in mice lacking CB1R expression in forebrain GABAergic neurons (GABA-CB1R−/−) and forebrain principal
neurons (CaMK-CB1R−/−). (A) HVS comparison in all experiments. Each line represents a single experiment, and different colors represent different animals.
CP55940 (0.3 mg/kg) reliably increases HVS in WT animals. Such effect is absent in GABA-CB1R−/− mice and small in CaMK-CB1R−/− mice. P values are from
Wilcoxon paired two-sided signed rank test. (B) Mean HVS change (CP55940/vehicle) + SEM for all experiments. P values are from Wilcoxon rank sum test vs.
WT data. Note that in GABA-CB1R−/− and CaMK-CB1R−/− mice, CB1R expression is absent from D1-positive striatonigral neurons.
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Fig. S5. Relative ECoG oscillatory content in control condition recorded from WT and CB1R conditional mutant mice. (A, Left) ECoG power spectrum density
function of a representative WT mouse, in control condition. Three frequency bands (1–4, 4–10, 10–20 Hz) were arbitrarily defined. ECoG was high-pass filtered
above 1 Hz. The three histograms show the ECoG relative power in the three bands during baseline or vehicle recordings for all experiments displayed in Figs.
2, 4, 5, and Fig. S4. P values are from Wilcoxon rank sum test vs. WT and were not graphically reported if above 0.05. (B) Same data as in A, except that the 1/f
power relationship was removed from the ECoG (7). In this case, the relative power in the lowest frequency band is meaningless and is not shown. Note that
there was no significant difference between WT and CB1 conditional mutant mice in the 10- to 20-Hz band.
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